Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.
For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.
The bit I cannot resolve on my own is what the phase 2 dropout pattern implies about how the phase 3 tolerability will read.
Numbers rather than impressions, if you have them.
Short answer first, then the reasoning. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.
PurityPaulOR said:Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…
Agreeing with PurityPaulOR, and the qualification matters more than the agreement. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.
That is the short version; the long version is somebody else's post.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsnewstart_MO said:Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.
Mine went the same way, slower. Posting only so the count is not one.
From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.